Sarcomatrix Therapeutics, Corp.
October 15, 2024
Hunt Room
We are on a mission to stabilize and regenerate muscle using novel, first-in-class drugs.
Muscle wasting diseases, such as muscular dystrophy, cachexia, and sarcopenia, create a significant burden, affecting over 2 billion people worldwide. These conditions lead to severe muscle atrophy, greatly diminishing patients' quality of life and increasing healthcare costs. Current therapies merely delay disease progression without offering a true solution.
At Sarcomatrix, we are pioneering treatments that address the root cause of these diseases. Our innovative approach combines gene-modifying oral drugs and protein replacement via IV, offering a potential cure rather than just symptom management. This positions us uniquely in a market where existing treatments fall short.